Loading cancer entity…
Loading cancer entity…
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05005715 | Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery | completed | Phase 2 | 64 | Seoul National University HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04042753 | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT01689727 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors | completed | Phase 2 | 40 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04863339 | Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery | withdrawn | Phase 2 | 0 | University of North Carolina, Chapel HillOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT02749227 | Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors(PASSILCORT) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04335357 | TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas | unknown | Phase 2 | 150 | Tiburio TherapeuticsINDUSTRY | 0 | Apr 6, 2020 | clinicaltrials |
| NCT04244708 | The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas | unknown | Phase 2 / Phase 3 | 150 | Peking Union Medical College HospitalOTHER | 0 | Jan 28, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT00929669 | Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas(LAR) | terminated | Phase 2 | 2 | University of PennsylvaniaOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT01203618 | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas | withdrawn | Phase 2 | 0 | MorphotekINDUSTRY | 1 | Nov 4, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00697814 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | completed | Phase 2 | 15 | Federal University of São PauloOTHER | 1 | Jun 16, 2008 | clinicaltrials |
| NCT00001860 | Sandostatin LAR Depot vs. Surgery for Treating Acromegaly | completed | Phase 2 | 5 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2026source: clinicaltrials